NEW YORK, January 1, 2026, 18:59 ET — Market closed
- CRISPR Therapeutics shares last closed down 1.4% at $52.44 on Dec. 31, the final session of 2025.
- U.S. benchmarks ended the year lower in light trading, while biotech ETFs were little changed.
- Focus turns to Jan. 2 trading and early-2026 updates tied to Casgevy’s rollout and the next earnings timetable.
Shares of CRISPR Therapeutics AG ended the last trading session of 2025 down 1.4% at $52.44. U.S. stock markets were closed on Thursday for New Year’s Day, according to the NYSE holiday calendar.
The pullback matters because CRISPR heads into 2026 with its first commercial product still early in launch and with investors seeking clearer signs of demand. The stock has tended to react sharply to shifts in sentiment around gene-editing drugmakers.
Traders are also looking ahead to the next set of checkpoints: read-throughs from partner Vertex Pharmaceuticals, which leads commercialization of Casgevy, and the timing of CRISPR’s next quarterly update. Until then, the shares can trade more like a high-beta biotech proxy than a company on a single catalyst.
Wall Street closed lower on Wednesday in light year-end trading, with the S&P 500 down 0.74% and the Nasdaq off 0.76%, Reuters reported. “It’s frankly hard to find an asset class that did poorly outside of the U.S. dollar,” said Scott Ladner, chief investment officer at Horizon. Reuters
Biotech gauges were mixed. The SPDR S&P Biotech ETF rose about 0.2%, while the iShares Nasdaq Biotechnology ETF was little changed; gene-editing peers Intellia Therapeutics and Beam Therapeutics slipped, while Editas Medicine ticked higher.
CRISPR’s commercial story revolves around Casgevy, a CRISPR/Cas9 gene-editing therapy that edits a patient’s cells outside the body before they are returned to the patient. U.S. regulators approved it for sickle cell disease in December 2023, and CRISPR later said the FDA cleared it for transfusion-dependent beta thalassemia.
Vertex now leads global development, manufacturing and commercialization of Casgevy and splits program costs and profits worldwide 60/40 with CRISPR, a filing showed. That setup leaves CRISPR investors watching Vertex’s commentary closely for a read on early commercial traction.
On Dec. 31, CRISPR traded between $52.35 and $53.44 and finished near the session low, with about 1.38 million shares changing hands, according to market data. For technical traders, that $52.35 low is an immediate reference point, while the day’s high marks the first nearby resistance zone.
Before the next session on Friday, investors will be watching whether year-start flows and the return of regular liquidity amplify moves in higher-risk biotech names. Macro signals are also back in play after the holiday, with traders looking for fresh clues on the interest-rate path and risk appetite.
Attention also shifts to the annual J.P. Morgan Healthcare Conference in San Francisco, where companies often use presentations to frame launch progress and pipeline priorities. Vertex said its CEO Reshma Kewalramani is scheduled to present on Jan. 12 at 5:15 p.m. ET, as JPM-week events get underway.
Earnings are the next known marker. CRISPR has not confirmed a date for its fourth-quarter report, but MarketBeat currently lists an estimated Feb. 10 release before the market opens based on prior reporting patterns.
For now, CRISPR enters 2026 on the back foot after the year’s final session and close to a near-term support level. Investors are likely to keep one eye on any fresh read-through on Casgevy’s rollout and another on the next company update that can reset expectations for the gene-editing group.
